A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

NCT04962724 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Radiolabelled Xevinapant 200 mg (Oral Solution)
DRUG: Radiolabelled Xevinapant 100 μg (IV Solution)
DRUG: Xevinapant 200 mg (Oral Solution)

Sponsor

Debiopharm International SA